NCT00331032View on ClinicalTrials.gov

VivaGel™ in Healthy Young Women

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions
Herpes Simplex II
Interventions
DRUG

3% w/w SPL7013 Gel

Twice-daily vaginal application of 3.5 g of VivaGel™ (Carbopol®-based gel with 3% w/w SPL7013) in single use pre-filled applicators.

DRUG

Placebo

Placebo gel (Carbopol®-based formulation alone) in single use pre-filled applicators.

Trial Locations (2)

40100

Kenya Medical Research Institute, Kisumu

94143

University of California San Francisco, San Francisco

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00331032 - VivaGel™ in Healthy Young Women | Biotech Hunter | Biotech Hunter